1 code implementation • 29 Jun 2022 • Yining Hua, Hang Jiang, Shixu Lin, Jie Yang, Joseph M. Plasek, David W. Bates, Li Zhou
Time-trend analysis indicated that Hydroxychloroquine and Ivermectin were discussed more than Molnupiravir and Remdesivir, particularly during COVID-19 surges.